SCHEMBL5456340

SCHEMBL5456340

Cc1cccc(NC(=O)Nc2sc3c(c2C(N)=O)CCOC3)c1C

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFTR P13569 2/20 0.60
ANO1 Q5XXA6 4/20 0.56
CNR2 P34972 4/20 0.50
CNR1 P21554 3/20 0.50
FLT3 P36888 3/20 0.47
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
EPHB4 P54760 1/20 0.46
KMT2A Q03164 1/20 0.46
PTPRC P08575 1/20 0.45
PTPN2 P17706 1/20 0.45
PTPN1 P18031 1/20 0.45
PTPRB P23467 1/20 0.45
PTPRE P23469 1/20 0.45
RAB7A P51149 1/20 0.44
KCNH2 Q12809 2/20 0.43
TLR2 O60603 1/20 0.43
CXCR2 P25025 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5457966 0.92 ANO1 (0.66) CFTRANO1CNR2CNR1FLT3
SCHEMBL5467763 0.90 CFTR (0.58) CFTRANO1CNR2CNR1MEN1
SCHEMBL5449480 0.90 CFTR (0.58) CFTRANO1CNR2CNR1FLT3
SCHEMBL5458406 0.87 CFTR (0.55) CFTRANO1CNR2CNR1MEN1
SCHEMBL5448477 0.84 CFTR (0.58) CFTRANO1CNR2CNR1FLT3
SCHEMBL5456284 0.84 CFTR (0.58) CFTRANO1CNR2CNR1FLT3
SCHEMBL5460609 0.84 CFTR (0.58) CFTRANO1CNR2CNR1FLT3
SCHEMBL5455040 0.84 CFTR (0.55) CFTRANO1CNR2CNR1FLT3
SCHEMBL5459139 0.84 CFTR (0.60) CFTRANO1CNR2CNR1FLT3
SCHEMBL5460026 0.84 CFTR (0.58) CFTRANO1CNR2CNR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885ANO1 3245/4885CNR2 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.